Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A...
Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis
About this item
Full title
Author / Creator
Publisher
Los Angeles, CA: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
Los Angeles, CA: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Use of blinded independent central review (BICR) has become more common in oncology phase 3 trials as progression-free survival (PFS) has been increasingly used as an endpoint for regulatory approval. Since PFS is primarily a radiographic endpoint, BICR has been implemented to assess and reduce potential bias in the local evaluation (LE) of PFS. Re...
Alternative Titles
Full title
Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2179218827
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2179218827
Other Identifiers
ISSN
2168-4790
E-ISSN
2168-4804
DOI
10.1177/0092861512459733
